Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

The management believes, that on account of ramp-up of existing products, Fermion contract, and potential commercialisation ...

Specifically, BMS is taking issue with a decision to deny its rebate plan for big-selling blood thinner Eliquis (apixaban) under the 340B federal drug discount programme – which requires ...

and Pfizer/Bristol-Myers Squibb's Eliquis (apixaban) – if treatment with the drugs leads to life-threatening or uncontrolled bleeding complications. On the positive side, members of the Cellular ...

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

Ami Organics recorded robust growth in the December 2024 quarter. While its revenue increased by 65% year-on-year, adjusted ...

A recent study investigates whether apixaban is superior to aspirin in preventing nonlacunar covert infarcts in patients with ...